Publicaciones en colaboración con investigadores/as de Icahn School of Medicine at Mount Sinai (17)

2023

  1. Cardiac Insulin Resistance in Subjects With Metabolic Syndrome Traits and Early Subclinical Atherosclerosis

    Diabetes Care, Vol. 46, Núm. 11, pp. 2050-2057

  2. Priorities in Cardio-Oncology Basic and Translational Science: GCOS 2023 Symposium Proceedings: JACC: CardioOncology State-of-the-Art Review

    JACC: CardioOncology, Vol. 5, Núm. 6, pp. 715-731

2022

  1. Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19

    Life science alliance, Vol. 5, Núm. 4

2021

  1. Clinical Validation of a 3-Dimensional Ultrafast Cardiac Magnetic Resonance Protocol Including Single Breath-Hold 3-Dimensional Sequences

    JACC: Cardiovascular Imaging, Vol. 14, Núm. 9, pp. 1742-1754

  2. Triglycerides and Residual Atherosclerotic Risk

    Journal of the American College of Cardiology, Vol. 77, Núm. 24, pp. 3031-3041

2020

  1. Association Between Left Ventricular Noncompaction and Vigorous Physical Activity

    Journal of the American College of Cardiology, Vol. 76, Núm. 15, pp. 1723-1733

  2. Enhanced MAPK1 Function Causes a Neurodevelopmental Disorder within the RASopathy Clinical Spectrum

    American Journal of Human Genetics, Vol. 107, Núm. 3, pp. 499-513

2017

  1. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication

    Heart Rhythm, Vol. 14, Núm. 1, pp. e3-e40

2016

  1. EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: Definition, characterisation, and clinical implication

    Journal of Arrhythmia, Vol. 32, Núm. 4, pp. 247-278

  2. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication

    Europace, Vol. 18, Núm. 10, pp. 1455-1490

  3. Impact of the Timing of Metoprolol Administration during STEMI on Infarct Size and Ventricular Function

    Journal of the American College of Cardiology, Vol. 67, Núm. 18, pp. 2093-2104

2015

  1. Prevalence, vascular distribution, and multiterritorial extent of subclinical atherosclerosis in a middle-aged cohort the PESA (Progression of Early Subclinical Atherosclerosis) study

    Circulation, Vol. 131, Núm. 24, pp. 2104-2113

2014

  1. Long-term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: Results from the Metocard-CNIC trial (Effect of Metoprolol in Cardioprotection during an Acute Myocardial Infarction)

    Journal of the American College of Cardiology, Vol. 63, Núm. 22, pp. 2356-2362

  2. Response to letter regarding article, "effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: The effect of metoprolol in cardioprotection during an acute myocardial infarction (METOCARD-CNIC) trial"

    Circulation

2013

  1. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: The effect of Metoprolol in Cardioprotection during an Acute Myocardial Infarction (METOCARD-CNIC) Trial

    Circulation, Vol. 128, Núm. 14, pp. 1495-1503

  2. The progression and early detection of subclinical atherosclerosis (PESA) study: Rationale and design

    American Heart Journal, Vol. 166, Núm. 6, pp. 990-998

  3. Treatment of idiopathic pulmonary fibrosis with Ambrisentan: A parallel, randomized trial

    Annals of Internal Medicine, Vol. 158, Núm. 9, pp. 641-649